Core Viewpoint - Scinai Immunotherapeutics Ltd. is actively participating in a roundtable discussion focused on the biopharma manufacturing ecosystem in Israel, highlighting the need for infrastructure to support early-stage development and clinical manufacturing [1][2][3][4][5][7]. Group 1: Roundtable Discussion Details - The roundtable titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale" will occur on January 19, 2026, at Expo Tel Aviv, co-led by Scinai's CEO Amir Reichman and senior representatives from the Manufacturers Association of Israel [2][3]. - The discussion aims to provide a realistic, fact-based examination of Israel's biopharma development and manufacturing ecosystem, focusing on early-stage development, CMC activities, and clinical manufacturing [3][4]. - Key topics will include access to laboratory infrastructure, CMC and analytical capabilities, and GMP manufacturing for clinical supply, which are essential for efficient development and regulatory readiness [4][5]. Group 2: Industry Context and Trends - The roundtable will also explore readiness for later-stage and commercial manufacturing in Israel, the role of local and international CDMOs, and the current scope of manufacturing capabilities and structural gaps [5][6]. - Global trends affecting biopharma manufacturing will be discussed, including the increasing complexity of biologic modalities, evolving regulatory expectations, and the reliance on specialized CDMOs, with a focus on how national capabilities should evolve over the next 5–10 years [6][7]. - The event is part of HealthIL Week, Israel's leading international conference for healthcare innovation, which gathers stakeholders from various sectors to address challenges in healthcare and life sciences [8].